Business description of INCYTE-CORPORATION from last 10-k form

Item 1.    Business

        This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. Often, these statements include the words "believe," "expect," "target," "anticipate," "intend," "plan," "seek," "estimate," "potential," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," "might," or "may," or the negative of these terms, and other similar expressions. These forward-looking statements include statements as to:

    •
    the discovery, development, formulation, manufacturing and commercialization of our compounds, our product candidates and JAKAFI;

    •
    conducting clinical trials internally, with collaborators, or with clinical research organizations;

    •
    our collaboration and strategic relationship strategy; anticipated benefits and disadvantages of entering into collaboration agreements;

    •
    our licensing, investment and commercialization strategies, including our plans to commercialize JAKAFI;

    •
    the regulatory approval process, including obtaining U.S. Food and Drug Administration and other international health authorities approval for our products in the United States and abroad;

    •
    the safety, effectiveness and potential benefits and indications of our product candidates and other compounds under development;

    •
    the timing and size of our clinical trials; the compounds expected to enter clinical trials; timing of clinical trial results;

    •
    our ability to manage expansion of our drug discovery and development operations;

    •
    future required expertise relating to clinical trials, manufacturing, sales and marketing;

    •
    obtaining and terminating licenses to products, compounds or technology, or other intellectual property rights;

    •
    the receipt from or payments pursuant to collaboration or license agreements resulting from milestones or royalties;

    •
    plans to develop and commercialize products on our own;

    •
    plans to use third party manufacturers;

    •
    expected expenses and expenditure levels; expected uses of cash; expected revenues and sources of revenues;

    •
    expected losses; fluctuation of losses;

    •
    our profitability; the adequacy of our capital resources to continue operations;

    •
    the need to raise additional capital;

    •
    the costs associated with resolving matters in litigation;

    •
    our expectations regarding competition;

    •
    our investments, including anticipated expenditures, losses and expenses;

    •
    our patent prosecution and maintenance efforts; and

    •
    our indebtedness, and debt service obligations.

        These forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those projected and include, but are not limited to:

    •
    our ability to successfully commercialize JAKAFI;

    •
    our ability to maintain at anticipated levels, reimbursement for JAKAFI from government health administration authorities, private health insurers and other organizations;

    •
    our ability to establish and maintain effective sales, marketing and distribution capabilities;

    •
    the risk of reliance on other parties to manufacture JAKAFI, which could result in a short supply of JAKAFI, increased costs, and withdrawal of regulatory approval;

    •
    our ability to maintain regulatory approvals to market JAKAFI;

    •
    our ability to successfully identify patients and achieve a significant market share in order to achieve or maintain profitability;

    •
    the risk of civil or criminal penalties if we market JAKAFI in a manner that violates health care fraud and abuse and other applicable laws, rules and regulations;

    •
    our ability to discover, develop, formulate, manufacture and commercialize our other product candidates;

    •
    the risk of unanticipated delays in research and development efforts;

    •
    the risk that previous preclinical testing or clinical trial results are not necessarily indicative of future clinical trial results;

    •
    risks relating to the conduct of our clinical trials;

    •
    changing regulatory requirements;

    •
    the risk of adverse safety findings;

    •
    the risk that results of our clinical trials do not support submission of a marketing approval application for our product candidates;

    •
    the risk of significant delays or costs in obtaining regulatory approvals;

    •
    risks relating to our reliance on third party manufacturers, collaborators, and clinical research organizations;

    •
    risks relating to the development of new products and their use by us and our current and potential collaborators;

    •
    risks relating to our inability to control the development of out-licensed drug compounds or drug candidates;

    •
    risks relating to our collaborators' ability to develop and commercialize product candidates;

    •
    costs associated with prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights;

    •
    our ability to maintain or obtain adequate product liability and other insurance coverage;

    •
    the risk that our product candidates may not obtain or maintain regulatory approval;

    •
    the impact of technological advances and competition;

    •
    the ability to compete against third parties with greater resources than ours;